Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Mantle-Cell 6Unspecified Adult Solid Tumor, Protocol Specific 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Colorectal Neoplasms 5Waldenstrom Macroglobulinemia 4Rectal Neoplasms 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Prolymphocytic 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3

Interventions

pembrolizumab 162Carboplatin 144Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 38Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × Pharmacogenomic Testing × Clear all
NCT01071564 2015-04-15

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
13 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡